Patents by Inventor Andrew Charles Payne

Andrew Charles Payne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
    Patent number: 11518803
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: December 6, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS
    Publication number: 20200407436
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 31, 2020
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE
    Publication number: 20200377578
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon MacKenzie, Matthew Cox
  • Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
    Patent number: 10766956
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • Neutralising antibodies to the major exotoxins TCDA and TCDB of
    Patent number: 10752676
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: August 25, 2020
    Assignee: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenzie, Matthew Cox
  • ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS
    Publication number: 20190330321
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 31, 2019
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • A Specific Trifluoroethyl Quinoline Analogue For Use In The Treatment of APDS
    Publication number: 20190209567
    Abstract: N—{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroethyl}-pyrido[3,2-d]pyrimidin-4-ylamine is effective in the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS).
    Type: Application
    Filed: May 15, 2017
    Publication date: July 11, 2019
    Inventors: Rodger Anthony Allen, Martin John Armstrong, Marina Cavazzana, Sven Kracker, Duncan Philip McHale, Andrew Charles Payne
  • NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE
    Publication number: 20140348844
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: September 10, 2012
    Publication date: November 27, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenze, Matthew Cox